OTLC Oncotelic Therapeutics, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 908259 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY14,923.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE181.6%
ROA117.3%
ROIC (approx.)-3.2%
Asset turnover—
Leverage & solvency
Liabilities / assets33.4%
Debt / equity0.00x
Current ratio0.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.01x
Accruals ratio118.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $250,000 | — | — | — | — | — | — |
| R&D expense | $1,622 | $345 | $795 | $3,337 | $426 | $297 | $297 | — |
| SG&A expense | $231,053 | $1.09M | $1.85M | $2.53M | $490,547 | $65,672 | $100,803 | $32,666 |
| Operating income | -$232,675 | -$843,565 | -$1.85M | -$2.53M | -$490,973 | -$65,969 | -$101,100 | -$31,454 |
| Interest expense | $286,727 | $318,292 | — | — | $231,338 | $207,780 | — | — |
| Net income | -$1.11M | $388,147 | -$2.19M | $250.35M | -$1.05M | $277,856 | -$298,716 | -$600,934 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 457.22M | 467.91M | 443.80M | — | 426.44M | 452.81M | 407.42M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $63,798 | $186,014 | $63,614 | $88,857 | $409,000 | $88,022 | $79,173 | $86,128 |
| Receivables | $2,057 | $2,058 | $2,058 | $51,324 | $3,976 | $18,976 | $18,976 | $18,976 |
| Current assets | $1.27M | $1.46M | $2.07M | $1.20M | $1.61M | $137,592 | $124,993 | $134,211 |
| Goodwill | $2.79M | $2.79M | $2.79M | $2.79M | $2.79M | $2.79M | $2.79M | $2.79M |
| Total assets | $393.81M | $394.75M | $393.96M | $393.09M | $28.16M | $26.68M | $26.67M | $26.68M |
| Current liabilities | $18.04M | $17.91M | $18.40M | $18.14M | $20.08M | $19.29M | $19.48M | $19.20M |
| Short-term debt | — | — | — | — | — | $2.72M | $2.58M | $2.42M |
| Total liabilities | $131.52M | $131.31M | $131.74M | $131.36M | $20.08M | $19.29M | $19.48M | $19.20M |
| Shareholders' equity | $263.47M | $264.56M | $263.29M | $262.76M | $9.05M | $8.30M | $8.02M | $8.25M |
| Shares outstanding | 457.51M | 457.01M | 444.20M | 442.60M | 439.45M | 408.29M | 408.29M | 407.29M |
| Cash flow statement | ||||||||
| Operating cash flow | -$342,216 | -$92,197 | -$342,243 | -$783,017 | -$307,022 | -$126,151 | -$166,955 | -$103,880 |
| Financing cash flow | $220,000 | $214,597 | $317,000 | $462,874 | $628,000 | $135,000 | $160,000 | $41,000 |
| Stock-based compensation | $63,389 | $730,410 | $1.64M | $2.20M | $183,742 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.